Loading
2 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | HR-positive |
|---|---|
| Other settings | 2 |
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| HR-positive | Well-differentiated tumour | Treated as HR-positive breast cancer. | 91 | ||
| HR-positive | Small cell or large cell neuroendocrine carcinoma | Surgery and the extrapulmonary neuroendocrine carcinoma pathway (platinum and etoposide, radiotherapy); no standard exists. | 81 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.